Frontiers in Pharmacology · 2018 · 22 citations · 35 references
MedicineMolecular GeneticsNeurologyMovement DisordersNeurogeneticsPathophysiologyDrug-induced Movement DisordersGenetic DisordersMovement Disorder GeneticsNeurodegenerative DiseasesNeurodegenerative DisordersParkinsonian DisordersAbnormal Involuntary Movement ScaleAntipsychotic-induced Movement DisordersAntipsychotic-induced Tardive DyskinesiaTardive DystoniaTardive Tremor
Tardive dyskinesia (TD) is a movement disorder that may occur after extended use of antipsychotic medications. The etiopathophysiology is unclear; however genetic factors play an important role. The Perlecan (HSPG2) gene was found to be significantly associated with TD in Japanese schizophrenia patients, and this association was subsequently replicated by an independent research group. To add to the evidence for this gene in TD, we conducted a meta-analysis specific to the relationship of HSPG2 rs2445142 with TD occurrence, while also adding our unpublished genotype data. Overall, we found a significant association of the G allele with TD occurrence (p=0.0001); however, much of the effect appeared to originate from the discovery dataset. Nonetheless, most study samples exhibit the same trend of association with TD for the G allele. Our findings encourage further genetic and molecular studies of HSPG2 in TD.
35
Haploview: analysis and visualization of LD and haplotype maps
Jeffrey C. Barrett, Ben Fry, Julian Maller et al. · Bioinformatics · 2004 · 14.7K citations · Full text
Perlecan is essential for cartilage and cephalic development
Eri Arikawa‐Hirasawa, Hideto Watanabe, Hiroya Takami et al. · Nature Genetics · 1999 · 542 citations
Tardive dyskinesia and new antipsychotics
Christoph U. Correll, Eva M Schenk · Current Opinion in Psychiatry · 2008 · 364 citations
Medicine, Neurology, Pharmacotherapy +13